Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation.
Anderlini
Paolo
P
Sheth
Sheetal
S
Hicks
Krystal
K
Ippoliti
Cindy
C
Giralt
Sergio
S
Champlin
Richard E
RE
D000293:Adolescent; D000328:Adult; D000368:Aged; D001549:Benzamides; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012008:Recurrence; D033581:Stem Cell Transplantation; D013997:Time Factors; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate